摘要
视网膜分支静脉阻塞（BRVO）继发黄斑水肿的抗血管内皮生长因子药物和糖皮质激素药物治疗在其治疗方法、治疗适宜的目标患者及治疗时间选择、治疗终点判断等方面均存在较多困惑,并且存在治疗周期长、易复发等不足.BRVO血管阻塞后的侧支循环以及循环再通研究探索值得未来研究中重视.既往临床实践中着眼于循环再通的溶栓、动静脉鞘膜切开手术、激光脉络膜视网膜血管吻合等治疗方法的合理性、有效性、安全性有待进一步证实.近年初现端倪的人工血管搭桥手术实验由于关键技术上仍存在瓶颈,尚不具备实用性,但为BRVO治疗提供了值得期待的新思路.
Pharmaceutical therapy,including anti-vascular endothelial growth factor treatment and intravitreal corticosteroids,is the most common treatment for branch retinal vein occlusion （BRVO） and its complications,however there are confusing ideas about the protocol,patient selection,timing and endpoint of this treatment.The disease is easy to relapse with these drugs therapy.Collateral vessel formation was found in patients receiving intravitreal injection of ranibizumab or triamcinolone for BRVO and secondary macular edema.The mechanism of collateral vessel formation has not been carefully investigated.In the past thrombolysis,arteriovenous fasciostomy and laser choroidal retinal vascular anastomosis were used to reconstruct the retinal circulation,but their rationality,effectiveness and safety need to be further were studied.In recent years,because of the key technology is still immature,the artificial vascular bypass surgery experiment is not yet practical,but provides us a new idea worth looking forward to for the treatment of BRVO.
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2017年第2期114-118,共5页
Chinese Journal of Ocular Fundus Diseases
